U.S. Biotechnology Market Size, Share & Trends Analysis Report By Technology (Nanobiotechnology, Tissue Engineering and Regeneration), By Application (Health, Food & Agriculture), And Segment- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The U.S. biotechnology market size was estimated at USD 552.49 billion in 2023 and is projected to hit around USD 1,794.11 billion by 2033, growing at a CAGR of 12.5% during the forecast period from 2024 to 2033.

Key Takeaways:

• DNA sequencing dominated this market and held the highest revenue market share of 18% in 2023
• The others’ segment is anticipated to grow at the fastest CAGR of 28.1% during the forecast period.
• The health segment dominated the market and accounted for the largest revenue market share of 44.13% in 2023.
• Bioinformatics is expected to witness the fastest growth, with a CAGR of 17.2% during the forecast period.

U.S. Biotechnology Market Growth

Government support plays a major role in propelling market growth, focusing on modernizing regulatory frameworks, enhancing approval processes and reimbursement policies, and standardizing clinical studies. The National Science Foundation (NSF) and Synthetic Biology Engineering Research Center (SynBERC) are responsible for conducting regular evaluations of synthetic biology. Biotechnology applications are experiencing a surge in market revenue thanks to the growth of personalized medicine and the development of orphan drug formulations. This has resulted in the emergence of many new and innovative biotech firms, contributing to the industry's expansion.

The U.S. accounted for over 35.6% of the global biotechnology market 2023. The increasing demand for agricultural products like wheat, rice, and beans, driven by population growth, highlights the importance of biotechnology-based solutions. Scientists focus on advanced agricultural technologies through extensive research and development (R&D) to address challenges such as pest attacks, limited land availability, and water scarcity. Moreover, investments in agriculture R&D, exemplified by companies like Loopworm and initiatives like the USD 101 million investment by Unilever and others in regenerative agriculture, propel market growth. Supportive government guidelines, particularly in synthetic biology, and the decreasing costs of DNA sequencing are also significant drivers of the biotechnology market's expansion.

The market has seen a positive influence from the COVID-19 pandemic, as it has spurred an increase in opportunities and advancements in developing and producing vaccines for the virus. Moreover, the success of mRNA vaccines and expedited approval processes have resulted in a spike in vaccine-related revenues, demonstrated by a collective revenue of approximately USD 31 billion in 2021 from vaccines by Moderna, Pfizer/BioNTech, and Johnson & Johnson. In addition, the growing demand for biotechnology tools in agricultural applications, such as micro-propagation, molecular breeding, tissue culturing, traditional plant breeding, and the creation of genetically modified crops, among others, has further propelled the market's growth.

In addition, an increasing tendency is observed toward accepting genetically modified crops and seeds that can endure insect-resistant herbicides. This trend is playing a significant role in the expansion of the market. A robust clinical trial pipeline and funding availability in tissue engineering and regeneration technologies further fuel the market growth. Moreover, the increasing need for effective clinical interventions to address chronic conditions like cancer, diabetes, age-related macular degeneration, and various forms of arthritis is expected to propel market growth. Leading companies are actively exploring and advancing pipeline products targeting conditions such as diabetes, neurological disorders including Parkinson's and Alzheimer's diseases, different types of cancers, and cardiovascular ailments. Notably, data from clinicaltrials.gov in January 2021 revealed 126 agents undergoing clinical trials for Alzheimer's disease treatment, with 28 treatments in phase III trials.

Fermentation technology is on the rise in the life sciences and healthcare industries, positively impacting market expansion. The development of simplified and vortex bioreactors and other improvements to traditional bioreactors has driven advancements in fermentation technology and increased its popularity. Additionally, vortex bioreactors have been upgraded for more efficient wastewater treatment. These advancements in fermentation technology are expected to fuel market growth.

In recent years, there has been a noticeable increase in the use of biotechnological methods such as stem cell technology, DNA fingerprinting, and genetic engineering. The growth in the market for stem cell technologies can be attributed to advancements in stem cell therapeutics, rising demand for biologics, and an increased emphasis on creating personalized medicines. DNA fingerprinting is becoming more prevalent in forensic science, and it's also being used to investigate familial relationships in animal populations and measure inbreeding levels. In a similar vein, the use of genetic engineering and cloning techniques is expanding in animal breeding and the production of complex biological substances.

U.S. Biotechnology Market Report Scope

Technology Insights

DNA sequencing dominated this market and held the highest revenue market share of 18% in 2023, which can be attributed to declining sequencing costs and rising penetration of advanced DNA sequencing techniques. This technology is key in creating personalized cancer treatments by pinpointing mutations. Widely embraced in research, DNA sequencing efficiently compares large DNA segments across species. Advancements in sequencing systems are enhancing speed and cost-effectiveness, offering substantial potential in healthcare applications. Government support, exemplified by grants like the USD 10.7 million NIH award in May 2021 for Alzheimer's disease research, is fueling the expansion of sequencing for disease insights.

The others’ segment is anticipated to grow at the fastest CAGR of 28.1% during the forecast period. This segment includes fermentation in food and environmental applications, driven by the rising use of microorganisms in the food industry and to address environmental challenges like climate change. Intechopen highlighted in February 2023 that employing microorganisms in food processing can boost efficiency, save time and energy, and establish a more consistent processing system commercially. With the modern lifestyle's demands, there is a growing reliance on processed foods, leading to an increased demand for such products. Fermentation in food processing leverages microorganisms' growth and metabolic activity to stabilize and transform food materials by converting organic acids or carbon dioxide and carbohydrates to alcohols under anaerobic conditions using bacteria, yeasts, or a combination of them. This is anticipated to fuel market growth.

Application Insights

The health segment dominated the market and accounted for the largest revenue market share of 44.13% in 2023. The use of biotechnology in healthcare is transforming the industry. Innovations in genomics, molecular biology, cellular and tissue engineering, bio-imaging, new drug discovery, and delivery methods offer promising possibilities for enhancing diagnostic capabilities and broadening treatment options. The segment's growth is expected to be driven by an increasing disease burden, the rising availability of agri-biotech and bio-services, and technological advancements in the bio-industrial sector. Furthermore, significant progress in Artificial Intelligence (AI), machine learning (ML), and big data is also fueling the segment's growth and boosting its adoption food and beverage industries.

Bioinformatics is expected to witness the fastest growth, with a CAGR of 17.2% during the forecast period. The bioinformatics industry has seen rapid global expansion, driven by various fields like physics, mathematics, and pharmaceuticals, and the emergence of new biotechnology fields like proteomics and genomics. The surge in data from increased biotechnology R&D has broadened bioinformatics’ scope. It’s now widely used for bioresource conservation & management, biology prospecting, product & process evaluation, and managing complex data for national programs. Cloud computing has become integral to bioinformatics, providing scalable computing & storage, data sharing, and on-demand resource access. The rise of biomedical cloud platforms catering to specific research community needs is a notable trend, expected to boost bioinformatics tool adoption in life sciences.

Recent Developments

• In October 2023, Amgen announced that it had completed its acquisition of Horizon Therapeutics plc. Horizon Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic and autoimmune diseases.
• In October 2023, Gilead Science's subsidiary, Kite and Epicrispr Biotechnologies, announced a research collaboration and licensing agreement to utilize Epic Bio's gene regulation platform in developing advanced cancer cell therapies.
• In September 2023, Biogen announced that the U.S. Food and Drug Administration (FDA) had approved CONFIDENCE (tocilizumab-above) in its intravenous form, representing a biosimilar monoclonal antibody concerning ACTEMRA.

Key U.S. Biotechnology Company Insights

The biotechnology sector is witnessing a trend where companies form alliances through various strategic initiatives such as business collaborations, partnerships, and development agreements. The primary motivation behind these initiatives is the collective development of innovative therapeutics for improved results and cost reduction. The market's growth is largely due to the launch of new and innovative products, contracts, acquisitions, technological advancements, and wide-ranging applicability. For instance, in January 2021, Sartorius Stedim Biotech acquired the chromatography process equipment division of Novasep. This division's chromatography products portfolio includes resin-based batch systems and advanced chromatography systems for various applications, including oligonucleotides, small molecules, insulin, and peptides.

Key U.S. Biotechnology Companies:

• AstraZeneca
• Gilead Sciences, Inc.
• Bristol-Myers Squibb
• Sanofi
• Biogen
• Abbott Laboratories
• Pfizer, Inc.
• Amgen Inc.
• Novo Nordisk A/S
• Merck KGaA
• Johnson & Johnson Services, Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Lonza

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Biotechnology market.

By Technology 

• Nanobiotechnology
• Tissue Engineering and Regeneration
• DNA Sequencing
• Cell-based Assays
• Fermentation
• PCR Technology
• Chromatography
• Others

By Application 

• Health
• Food & Agriculture
• Natural Resources & Environment
• Industrial Processing
• Bioinformatics
• Others